Comparison of Micro- and Macrovascular Disease(s) in People With T2D, Who Have Moderate to Severe Acanthosis Nigricans vs. Those Who do Not Have Acanthosis Nigricans

Launched by DIABETES FOUNDATION, INDIA · Apr 24, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating how moderate to severe acanthosis nigricans—a skin condition that causes dark, velvety patches—affects people with Type 2 Diabetes Mellitus (T2D) compared to those who do not have this skin condition. The researchers believe that individuals with acanthosis nigricans may experience more serious complications related to their diabetes, such as eye problems, nerve damage, and kidney issues. By studying these two groups, the trial aims to understand the relationship between this skin condition and the severity of diabetes-related complications.

To participate in the trial, individuals must be between 20 and 70 years old and diagnosed with T2D for up to 30 years. They should have a body mass index (BMI) of more than 25 but less than 40 and display mild, moderate, or severe acanthosis nigricans. Participants will undergo a thorough health assessment, including checks for various diabetes complications. This study is open to both men and women, and it's currently recruiting participants. If you or someone you know fits the criteria and is interested in contributing to this important research, please consider reaching out for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with T2DM (up to 30 years Duration)
• • 2. Age 20 to 70 years
• • 3. BMI \>25 kg/m² to \>40 kg/m²
• • 4. Gender- Both (Male \& Female)
• • 5. Mild, Moderate and Severe Acanthosis
• Exclusion Criteria:
• • 1. Alcoholic with Moderate to Severe.
• • 2. BMI \>40 kg/m²
• • 3. Congestive heart disease
• • 4. Positive hepatitis B or hepatitis C, secondary causes of fatty liver (eg. consumption of amiodarone and tamoxifen) and congestive hepatopathy.
• • 5. Severe end organ damage or chronic diseases: renal/hepatic failure, any malignancy, major systemic illness etc.